ACTG A5186

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。A5186是一项II期、随机、开放标签、多中心试验，旨在确定鱼油联合非诺贝特在接受高效抗逆转录病毒治疗（HAART）且血清甘油三酯（TG）升高的HIV感染受试者中的疗效和安全性。对任何一种药物单独治疗均无反应。主要目的：评价鱼油补充剂单独或与非诺贝特联合治疗血清甘油三酯升高的HIV感染人群的安全性和耐受性。评价鱼油补充剂与非诺贝特联合治疗是否会将任一药物单独治疗无效的受试者的血清甘油三酯（TG）降至3200 mg/dL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5186 is a phase II, randomized, open-label, multi-site trial to determine the efficacy and safety of fish oil combined with fenofibrate in HIV-infected subjects on highly active antiretroviral therapy (HAART) with elevated serum triglycerides (TG) who are not responding to either agent alone. Primary Objectives: To evaluate the safety and tolerability of fish oil supplement alone or in combination with Fenofibrate in an HIV-infected population with elevated serum TG.To evaluate whether the combination of fish oil supplement and Fenofibrate will decrease serum triglycerides (TG) to 3200 mg/dL in subjects not responding to either agent alone